Presentation is loading. Please wait.

Presentation is loading. Please wait.

Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute.

Published byLeo Lloyd Modified over 6 years ago

Similar presentations

Presentation on theme: "Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute."— Presentation transcript:

1 Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study by Thomas C. Abshire, Brad H. Pollock, Amy L. Billett, Patricia Bradley, and George R. Buchanan Blood Volume 96(5): September 1, 2000 ©2000 by American Society of Hematology

2 Box and wisker plot of the distribution of mean asparaginase levels for those with complete response (M1 marrow) versus no response (M2 or M3 marrow) at the end of induction.The mean value of each group is represented by the closed square, the median value ... Box and wisker plot of the distribution of mean asparaginase levels for those with complete response (M1 marrow) versus no response (M2 or M3 marrow) at the end of induction.The mean value of each group is represented by the closed square, the median value is the horizontal line within the box and the top and bottom lines delineate the 95% confidence interval. Thomas C. Abshire et al. Blood 2000;96: ©2000 by American Society of Hematology

Download ppt "Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute."

Similar presentations

A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.

A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? by Ching-Hon Pui, Charles G. Mullighan, William E. Evans, and Mary.

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? by Ching-Hon Pui, Charles G. Mullighan, William E. Evans, and Mary.
Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning  Jamie H. Zao, Tal Schechter, Wenchao Jessica.

Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning  Jamie H. Zao, Tal Schechter, Wenchao Jessica.
The influence of high-altitude living on body iron

The influence of high-altitude living on body iron
Hyperdiploid Acute Lymphoblastic Leukemia With 51 to 65 Chromosomes: A Distinct Biological Entity With a Marked Propensity to Undergo Apoptosis by Chikako.

Hyperdiploid Acute Lymphoblastic Leukemia With 51 to 65 Chromosomes: A Distinct Biological Entity With a Marked Propensity to Undergo Apoptosis by Chikako.
by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and

by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
Lucky Jain, MD, MBA  Clinics in Perinatology 

Lucky Jain, MD, MBA  Clinics in Perinatology 
Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology.

Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology.
Next-generation leukemia immunotherapy

Next-generation leukemia immunotherapy
VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population by Daniel B. Bellissimo,

VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population by Daniel B. Bellissimo,
Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic.

Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic.
In utero transplantation may soon be in delivery

In utero transplantation may soon be in delivery
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.
Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,

Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11):3909-3918 June 1, 1997 ©1997.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Does the effect of staying in school until age 16 depend on the BMI PGS? Bars show 2SLS point estimates of effect of staying in school until age 16 on.

Does the effect of staying in school until age 16 depend on the BMI PGS? Bars show 2SLS point estimates of effect of staying in school until age 16 on.
Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

Similar presentations

Ads by Google